The study by Li et al. showed that exosomes from bone marrow mesenchymal stem cells (BM-MSCs) modified with siRNA against GRP78 effectively delivered the siRNA to hepatocellular carcinoma cells, downregulated GRP78, and restored sorafenib sensitivity. The gene discussed is HSPA5; the disease is hepatocellular carcinoma.